Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
A 25-year-old female developed partial loss of smell 2 days after the injection of the AstraZeneca vaccine (first injection). The taste evaluation was normal. Patient did not take any medication and did not follow olfactory training. She reported that the smell disorder lasted 10 days. Patient did not report adverse event after the second vaccine injection. A 27-year-old female experienced loss of smell after the first injection of the AstraZeneca vaccine. The patient medical history was unremarkable. She perceived an improvement of smell sense 9 days after the vaccine without olfactory training or medical treatment. Patient did not report adverse event after the second vaccine injection. A 51-year-old female developed total loss of smell 2 days after the first injection of AstraZeneca vaccine. She also reported arthralgia, fever, and chills during a few days. The total loss of smell persisted one week with a subsequent progressive improvement of smell. The patient report...
A previously healthy woman in her 60s had mild fever and uneventful course after the 1st dose of ChAdOx1 nCoV-19 vaccine, but developed behavioral problems and refusal to take food, one day after receiving the second dose of ChAdOx1 nCoV-19 vaccination (dose interval 84 days). Her condition progressed rapidly with onset of confusion, forgetfulness, and hallucinations within the next 5 days. Over the next two days, the patient developed difficulty in walking and echolalia. She was prescribed amantadine, trihexyphenidyl and clonazepam by a local practitioner but she showed further deterioration in the form of irritability, incoherent speech, aggravated forgetfulness, auditory and visual hallucinations, abnormal movements of limbs, and jaw and neck dystonia. The patient had a serum anti-Spike protein IgG titer of 1891.5 AU/mL (non-reactive<50 AU/mL) at 37 days post-second dose. An initial magnetic resonance imaging (MRI) of the brain had revealed FLAIR hyperintensity in bila...
A previously healthy 28-year-old woman received the primary dose of adenovirus type 26 (Ad26) viral vector-based COVID-19 vaccine 35 (Janssen Pharmaceuticals, Johnson & Johnson vaccine ). A few days later, she developed a swelling at the injection site. Over the next three months, the nodule progressively enlarged to become a plaque with associated pain, warmth, and tingling sensation. She also developed cervical and left axillary lymphadenopathy, intermittent fevers, fatigue, and unintentional weight loss. Presumptive treatment for cellulitis with several courses of oral antibiotics was ineffective. According to the WHO-EORTC classification, the clinical and histopathologic findings were consistent with SPTCL - Subcutaneous panniculitis-like T-cell lymphoma, a rare type of lymphoma that mainly affects the skin . Lymphomas are cancers that result from a type of white blood cell that grows out of control. T-cell lymphoma begins in white bloo...
Comments
Post a Comment